Results of time-of-flight transmission measurements for 197Au at a 50 m station of GELINA

Transmission measurements have been performed at the time-of-flight facility GELINA to determine the total cross section for neutron induced reactions in 197Au. The measurements have been carried out at a 50 m transmission station of GELINA with the accelerator operating at 800 Hz. This report provides the experimental details required to deliver the data to the EXFOR data library which is maintained by the Nuclear Data Section of the IAEA and the Nuclear Energy Agency of the OECD. The experimental conditions and data reduction procedures are described. In addition, the full covariance information based on the AGS concept is given such that nuclear reaction model parameters together with their covariances can be derived in a least squares adjustment to the data.JRC.D.4-Standards for Nuclear Safety, Security and Safeguard

Determination of the 338 eV, 1098 eV and 1370 eV s-wave resonance parameters for neutron induced reactions of 55Mn at GELINA

In this report new values for the resonance parameters of the 338 eV, 1098 eV and 1370 eV s-wave resonances of 55Mn are presented. The parameters were derived from a resonance shape analysis of transmission and capture data resulting from measurements at the time-of-flight facility GELINA. Special samples have been prepared to optimize the transmission at the resonance dips, to avoid the impact of sample inhomogeneities and to reduce bias effects due to multiple interaction events and the normalization of the capture data. The parameters have been adopted in an ENDF-6 compatible file which has been tested and implemented in the next release of the Joint Evaluated Fission and Fusion data library, i.e. JEFF-3.2, which is maintained by the Nuclear Energy Agency of the OECD.JRC.D.4-Standards for Nuclear Safety, Security and Safeguard

Results of time-of-flight transmission measurements for 63,65Cu and natCu at a 50 m station of GELINA

Transmission measurements have been performed at the time-of-flight facility GELINA to determine neutron resonance parameters for 63Cu and 65Cu. The experiments have been carried out at a 50 m transmission station at a moderated neutron beam using a Li-glass scintillator with the accelerator operating at 800 Hz. Measurements were performed with a natCu metallic sample and metallic samples enriched in 63Cu and 65Cu. This report describes the experimental details required to deliver the experimental transmission to the EXFOR data library which is maintained by the Nuclear Energy Agency of the OECD and the Nuclear Data Section of the IAEA. The experimental conditions and data reduction procedures are described. In addition, the full covariance information based on the AGS concept is given, such that resonance parameters together with their covariances can be derived in a least squares adjustment to the data.JRC.D.4-Standards for Nuclear Safety, Security and Safeguard

JRC support to JAEA on the development of neutron resonance densitometry

The activities carried out during 2013 at the Institute for Reference Materials and Measurements of the Joint Research Centre of the European Commission to support the Japan Atomic Energy Agency in the development of Neutron Resonance Densitometry are described. These activities include experiments carried out at the time-of-flight facility GELINA, development of a model to account for sample inhomogeneities, assistance in data reduction and analysis procedures, preparation of test samples, training of JAEA staff and dissemination of the results.JRC.D.4-Standards for Nuclear Safety, Security and Safeguard

A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis

Objective: To evaluate the immunogenicity, safety, and efficacy of etanercept (ETN) manufactured using the serum-free, high-capacity manufacturing (SFHCM) process in patients with rheumatoid arthritis (RA). ----- Methods: In this global, multicenter, open-label, single-arm study (NCT02378506), 187 adult patients with moderate to severe RA received ETN 50 mg once weekly for 24 weeks manufactured using the SFHCM process. Immunogenicity (presence of antidrug antibodies (ADAs) and neutralizing antibodies (NAbs)) was assessed at 12 and 24 weeks. Safety and efficacy were evaluated at 4, 12, and 24 weeks. ----- Results: Eight (4.5%) patients tested positive for ADA, and there were no NAbs detected at any time throughout the study. Ninety (48.1%) patients reported treatment-emergent adverse events (AEs), of which 27 (14.4%) reported injection-site reactions, and 43 (23.0%) reported infections. The majority of AEs were mild or moderate in severity, and the drug was well tolerated. Throughout the duration of the study (week 4 to week 24), there was a progressive increase in the American College of Rheumatology (ACR)-defined responses (ACR20: 55.9%–82.0%, ACR50: 16.1%–57.8%, and ACR70: 3.2%–26.7%) from baseline and the proportion of patients achieving low disease activity and remission, with a corresponding decrease in measures of disease activity. ----- Conclusion: The immunogenicity, safety, and efficacy of ETN manufactured using the SFHCM process were similar to the current approved ETN formulation. ClinicalTrials.gov registration: NCT02378506

Studies Needed to Address Public Health Challenges of the 2009 H1N1 Influenza Pandemic: Insights from Modeling

In light of the 2009 influenza pandemic and potential future pandemics, Maria Van Kerkhove and colleagues anticipate six public health challenges and the data needed to support sound public health decision making.The authors acknowledge support from the Bill & Melinda Gates Foundation (MDVK, CF, NMF); Royal Society (CF); Medical Research Council (MDVK, CF, PJW, NMF); EU FP7 programme (NMF); UK Health Protection Agency (PJW); US National Institutes of Health Models of Infectious Disease Agent Study program through cooperative agreement 1U54GM088588 (ML); NIH Director's Pioneer Award, DP1-OD000490-01 (DS); EU FP7 grant EMPERIE 223498 (DS); the Wellcome Trust (DS); 3R01TW008246-01S1 from Fogerty International Center and RAPIDD program from Fogerty International Center with the Science & Technology Directorate, Department of Homeland Security (SR); and the Institut de Veille Sanitaire Sanitaire funded by the French Ministry of Health (J-CD). The funders played no role in the decision to submit the article or in its preparation